Clinical Trial: A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes

U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07351058) titled 'A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes' on Jan. 16.

Brief Summary: The purpose of this study is to assess the efficacy and safety of RO7795068, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).

Study Start Date: Feb. 27

Study Type: INTERVENTIONAL

Condition: Obesity or Overweight Type 2 Diabetes Mellitus

Intervention: COMBINATION_PRODUCT: Placebo

Pl...